Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Research into the neural mechanisms underlying the symptoms of parkinsonism utilizing the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primate model have shown that the subthalamic nucleus (STN) occupies a central role. As a logical development of this theory, we have studied the effects of thermocoagulative lesions of the STN in the primate model. Such lesions can cause remarkable symptom reversal in the experimental primate model.


Journal article


Br J Neurosurg

Publication Date





575 - 582


1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Animals, Fluorescent Antibody Technique, Macaca fascicularis, Parkinson Disease, Secondary, Substantia Nigra, Tegmentum Mesencephali, Treatment Outcome, Tyrosine 3-Monooxygenase